Physician profile
Stefanie K Wolf
NPI 1689028656
$3,769.30
in general payments reported to CMS, 2019-2025
30 companies · $602 in 2025
The $602 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.08 · 2022: $628 · 2023: $1,258 · 2024: $1,251 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,111.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $660.91 | 2022-2025 | Vumerity, Tysabri, Spinraza |
| Abbvie INC. | $541.61 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Sk Life Science, INC. | $500.99 | 2022-2025 | |
| Lilly USA, LLC | $348.68 | 2022-2025 | Emgality, Reyvow, Kisunla |
| Ucb, INC. | $236.90 | 2023-2025 | Briviact, Nayzilam, Rystiggo |
| Emd Serono, INC. | $222.59 | 2023-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $175.15 | 2023-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $132.61 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $106.09 | 2022-2024 | Soliris |
| Eisai INC. | $103.12 | 2024-2025 | |
| Mdd US Operations, LLC | $100.19 | 2022-2024 | Gocovri, Gocovri |
| Amneal Pharmaceuticals LLC | $94.53 | 2022-2024 | Rytary |
| Allergan, INC. | $62.99 | 2022 | |
| Jazz Pharmaceuticals INC. | $59.78 | 2022-2023 | |
| Impel Pharmaceuticals INC. | $58.85 | 2023 | Trudhesa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $51.08 | 2022-2023 | Aimovig |
| Neurelis, INC. | $43.69 | 2023 | Valtoco |
| Lundbeck LLC | $38.69 | 2024 | Rexulti |
| Pfizer INC. | $33.68 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.28 | 2024 | Hyqvia |
| Livanova USA, INC. | $24.94 | 2022 | |
| Tandem Diabetes Care, INC. | $18.13 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.74 | 2024 | |
| Genentech USA, INC. | $17.58 | 2024 | Ocrevus |
| Banner Life Sciences, LLC | $16.49 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.94 | 2024 | Rexulti |
| Abbott Laboratories | $15.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.00 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.14 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.